Advancing Novel Countermeasures for Opioid-Induced Respiratory Depression
A novel, cell-penetrant thiol ester countermeasure engineered to reverse opioid-induced respiratory failure and alveolar-arterial gradient mismatch without compromising antinociception or sedation.
Opioid-induced respiratory depression (OIRD) drives fatal overdose via disruptions to brainstem ventilatory control and cellular redox homeostasis. Standard opioid receptor antagonists (e.g., naloxone) reverse respiratory depression but indiscriminately strip necessary analgesia and induce acute withdrawal.
Thiopeutics is developing D-cysteine ethyl ester (D-CYSee). Preclinical in vivo models demonstrate that D-CYSee rapidly corrects minute ventilation, arterial blood-gas chemistry (pH, pO2, pCO2), and ventilation-perfusion mismatch while strictly preserving the analgesic efficacy of the primary opioid.